(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Patients with inadequate health insurance were more likely to receive mastectomy, omit RT following breast-conserving surgery, and receive PMRT. Differences in clinical presentation and demographics according to insurance status incompletely explain the variation in therapy. Further study is needed to validate and address these disparities and to evaluate the impact of health insurance legislative efforts in localized breast cancer.

Thomas M. Churilla, MD, Brian Egleston, PhD, Joshua Meyer, MD, Yanqun Dong, MD, PhD, Penny Anderson, MD; Fox Chase Cancer Center

INTRODUCTION: Various studies have suggested disparities in breast cancer care due to inadequate health insurance coverage. The purpose of our study was to test for associations between patient insurance status and the presentation and local therapy patterns among a large, nationally representative cohort of patients with localized breast cancer.

METHODS: We queried the National Cancer Institute (NCI) Survival, Epidemiology, and End Results (SEER) database for breast cancer cases diagnosed from 2007–2011 in women aged 18–64 years, limited to ductal or lobular histology, nonmetastatic stage, and treated with mastectomy or lumpectomy. Patients ≥ 65 years were excluded based on their eligibility for Medicare. We characterized clinical and demographic variables according to insurance status (insured vs Medicaid vs uninsured). We tested for associations between patient insurance status and choice of definitive surgical procedure (mastectomy vs breast-conserving surgery), omission of radiation therapy (RT) following breast-conserving surgery, and administration of postmastectomy RT (PMRT). We calculated odds ratios (ORs), performed Pearson’s chi-square test for univariable analysis, and used multiple logistic regression analysis to adjust for clinical and demographic covariates.

RESULTS: A total of 129,565 patients with localized breast cancer were analyzed. The health insurance statuses included insured (84.5%), Medicaid (11.5%), uninsured (2.1%), and unknown (1.9%). Patients with Medicaid or uninsured status were more likely to present with large, node-positive tumors and be black or unmarried and reside in low-income counties. The breast-conserving surgery rate was 51.3% among all patients and varied according to insurance status: insured (52.2%), uninsured (47.7%), and Medicaid (45.2%) (P < .001). Medicaid insurance status remained significantly associated with receipt of mastectomy in the multivariable analysis (OR =1.07; 95% confidence interval [CI], 1.03–1.11; P < .001). Radiation therapy was more frequently omitted after breast-conserving surgery in both Medicaid (OR = 1.14; 95% CI, 1.07–1.21) and uninsured (OR = 1.29; 95% CI, 1.14–1.47) patients in the multivariable analysis (P < .001 for both). PMRT was more frequently administered among Medicaid and uninsured patients; however, only Medicaid status remained significantly associated with PMRT in the multivariable analysis (OR = 1.10; 95% CI, 1.04–1.18; P = .002).

CONCLUSION: Patients with inadequate health insurance were more likely to receive mastectomy, omit RT following breast-conserving surgery, and receive PMRT. Differences in clinical presentation and demographics according to insurance status incompletely explain the variation in therapy. Further study is needed to validate and address these disparities and to evaluate the impact of health insurance legislative efforts in localized breast cancer.

Proceedings of the 97th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
Related Content